Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPME1 | Q9Y570 | 2/20 | 0.41 |
| ▸ | APEH | P13798 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27662268 | 0.85 | PPME1 (0.49) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2718306 | 0.80 | LMNA (0.49) | LMNAALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5534274 | 0.79 | LMNA (0.48) | SMN1; SMN2LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL1365701 | 0.79 | PKM (0.51) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL17900455 | 0.78 | PPME1 (0.49) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL17574711 | 0.75 | MEN1 (0.55) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL26054592 | 0.75 | PPME1 (0.46) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL765801 | 0.74 | PPME1 (0.47) | LMNAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL15188900 | 0.74 | PPME1 (0.46) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL4678724 | 0.74 | RAPGEF4 (0.51) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | SMN1; SMN2 4098/4885LMNA 4783/4885KDM4E 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.